A three-protein signature and clinical outcome in esophageal squamous cell carcinoma

Oncotarget

Volumn 6, Issue 7, 2015, Pages 5435-5448

  Cao, Hui Hui ^a,c   Zhang, Shi Yi ^b   Shen, Jin Hui ^b   Wu, Zhi Yong ^b   Wu, Jian Yi ^a   Wang, Shao Hong ^b   Li, En Min ^a   Xu, Li Yan ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SHANTOU CENTRAL HOSPITAL   (China)

^c ZHUHAI PEOPLE S HOSPITAL ZHUHAI HOSPITAL AFFILIATED WITH JINAN UNIVERSITY   (China)

Author keywords

ESCC; Kindlin 2; Myosin 9; Prognosis; Three protein signature

Indexed keywords

COFILIN 1; CYTOSKELETON PROTEIN; EZRIN; FASCIN; KINDLIN 2; LIPOCORTIN 2; METASTASIS SUPPRESSOR 1 PROTEIN; MOESIN; MYOSIN 9; PROFILIN 1; RAC1 PROTEIN; RADIXIN; RHO ASSOCIATED COILED COIL PROTEIN KINASE 2; TALIN; TENSIN; UNCLASSIFIED DRUG; VILLIN 1; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR RECURRENCE; ALGORITHM; CANCER GRADING; COHORT ANALYSIS; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FOLLOW UP; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ALGORITHMS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84925018228     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3102     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 12: 11-30.
2. Evans JA, Early DS, Chandraskhara V, Chandraskhara V, Chathadi KV, Fanelli RD, Fisher DA, Foley KQ, Hwang JH, Jue TL, Pasha SF, Sharaf R, Shergill AK, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc. 2013; 77: 328-34.
3. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003; 33: 49-54.
4. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005; 5: 845-56.
5. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133-44.
6. De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M,et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res. 2010; 16: 1532-41.
7. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, et al. A Five-Gene Signature and Clinical Outcome in Non-Small-Cell Lung Cancer. N Engl J Med. 2007; 356: 11-20.
8. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004; 350: 1828-37.
9. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, et al. Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. N Engl J Med. 2008; 359: 1995-04.
10. Paik S, Shak S, Tang G, Domenech G, Cheung NK, Oberthuer A, Fischer M, Maris JM, Brodeur GM, Hero B, Rodríguez E, Suñol M, Galvan P, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-26.
11. Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among Gene-Expression-Based Predictors for Breast Cancer. Ann Oncol. 2012; 23: 2866-73.
12. Potti A, Mukherjee S, Petersen R et al. A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2006; 355: 570-80.
13. Sveen A, Ågesen TH, Nesbakken A, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR. ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients. Clin Cancer Res. 2012; 18: 6001-10.
14. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, et al. Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. N Engl J Med. 2008; 359: 1995-04.
15. van Malenstein H, Gevaert O, Libbrecht L, Daemen A, Allemeersch J, Nevens F, Van Cutsem E, Cassiman D, De Moor B, Verslype C, van Pelt J. A Seven-Gene Set Associated with Chronic Hypoxia of Prognostic Importance in Hepatocellular Carcinoma. Clin Cancer Res. 2010; 16: 4278-88.
16. Mitra AP, Cote RJ. Development and prospective evaluation of a 20-gene model for molecular nodal staging of bladder cancer. Expert Rev Anticancer Ther. 2011; 11: 849-52.
17. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, et al. Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. N Engl J Med. 2010; 362: 875-85.
18. Garcia I, Mayol G, Ríos J et al. A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clin Cancer Res. 2012; 18: 2012-23.
19. Peters CJ, Rees JR, Hardwick RH, Domenech G, Cheung NK, Oberthuer A, Fischer M, Maris JM, Brodeur GM, Hero B, Rodríguez E, Suñol M, Galvan P, et al. A 4-Gene Signature Predicts Survival of Patients With Resected Adenocarcinoma of the Esophagus, Junction, and Gastric Cardia. Gastroenterology. 2010; 139: 1995-04.
20. Alan Hall. The cytoskeleton and cancer. Cancer Metastasis Rev. 2009; 28: 5-14.
21. Qi YJ, Chao WX, Chiu JF. An overview of esophageal squamous cell carcinoma proteomics. J Proteomics. 2012; 75: 3129-37.
22. Winder SJ, Ayscough KR. Actin-binding proteins. J Cell Sci. 2005; 118: 651-54.
23. Zhang X, Liu S, Guo C, Zong J, Sun MZ. The association of annexin A2 and cancers. Clin Transl Oncol. 2012; 14: 634-40.
24. Duncan R, Carpenter B, Main LC, Telfer C, Murray GI. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 2008; 98: 426-33.
25. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 2006; 81: 146-56.
26. Feng JG, Liu Q, Qin X et al. Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas. Mol Biol Rep. 2012; 39: 1267-74.
27. Falsey RR, Marron MT, Gunaherath GM, Geng YH, Zheng ST, Liu T, Sheyhidin I, Lu XM. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol. 2006; 2: 33-38.
28. Fatimathas L, Moss SE. Annexins as disease modifiers. Histol Histopathol. 2010; 25: 527-32.
29. Gozgit JM, Pentecost BT, Marconi SA, Otis CN, Wu C, Arcaro KF. Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer. Mol Cancer Res. 2006; 4: 905-13.
30. Shen Z, Ye Y, Kauttu T, Seppänen H, Vainionpää S, Wang S, Mustonen H, Puolakkainen P. Novel focal adhesion protein kindlin-2 promotes the invasion of gastric cancer cells through phosphorylation of integrin β1 and β3. J Surg Oncol. 2013; 108: 106-12.
31. Kato K, Shiozawa T, Mitsushita J, Toda A, Horiuchi A, Nikaido T, Fujii S, Konishi I. Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas. Hum Pathol. 2004; 35: 55-60.
32. Shi X, Wu C. A suppressive role of mitogen inducible gene-2 in mesenchymal cancer cell invasion. Mol Cancer Res. 2008; 6(5: 715-24.
33. Gong X, An Z, Wang Y, Guan L, Fang W, Strömblad S, Jiang Y, Zhang H. Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death. Cancer Lett. 2010; 299: 54-62.
34. Derycke L, Stove C, Vercoutter-Edouart AS, De Wever O, Dollé L, Colpaert N, Depypere H, Michalski JC, Bracke M. The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells. Int J Dev Biol. 2011; 55: 835-40.
35. Liang S, He L, Zhao X, Miao Y, Gu Y, Guo C, Xue Z, Dou W, Hu F, Wu K, Nie Y, Fan D. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One. 2011; 6: e18409.
36. Xia ZK, Yuan YC, Yin N, Yin BL, Tan ZP, Hu YR. Nonmuscle myosin IIA is associated with poor prognosis of esophageal squamous cancer. Dis Esophagus. 2012; 25: 427-36.
37. Zhang FR, Tao LH, Shen ZY, Lv Z, Xu LY, Li EM. Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem. 2008; 56: 193-99.
38. Zhao Q, Shen JH, Shen ZY, Wu ZY, Xu XE, Xie JJ, Wu JY, Huang Q, Lu XF, Li EM, Xu LY. Phosphorylation of Fascin Decreases the Risk of Poor Survival in Patients With Esophageal Squamous Cell Carcinoma. J Histochem Cytochem. 2010; 58: 979-88.
39. Sun LL, Sun XX, Xu XE, Zhu MX, Wu ZY, Shen JH, Wu JY, Huang Q, Li EM, Xu LY. Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma. Acta Histochem. 2013; 115: 56-62.
40. Xu QX, Li EM, Zhang YF, Liao LD, Xu XE, Wu ZY, Shen JH, Xu LY. Overexpression of sigma1 receptor and its positive associations with pathologic TNM classification in esophageal squamous cell carcinoma. J Histochem Cytochem. 2012; 60: 457-66.
41. Alldridge L, Metodieva G, Greenwood C, Al-Janabi K, Thwaites L, Sauven P, Metodiev M. Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry. J Proteome Res. 2008; 7: 1458-69.
42. Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, Yang GH, Ji Y, Fan J. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010; 59: 953-62.
43. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R. A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis. Clin Cancer Res. 2011; 17: 1490-01.
44. Garcia I, Mayol G, Ríos J, et al. A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clin Cancer Res. 2012; 18: 2012-23.